Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice

• Published in: Current treatment options in oncology 2023-08, Vol.24 (8), p.907-928
• Main Authors: Rios-Olais, Fausto Alfredo, Hilal, Talal
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; B-cell receptor; Chronic lymphocytic leukemia; Clinical medicine; Clinical trials; Humans; Immunotherapy - methods; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - etiology; Lymphocytes B; Medicine; Medicine & Public Health; Neoplasm, Residual - diagnosis; Oncology; Topical Collection on Lymphoma
• ISSN: 1527-2729; 1534-6277; 1534-5277
• DOI: 10.1007/s11864-023-01103-1

Opinion statement Treatment of chronic lymphocytic leukemia (CLL) has evolved dramatically during the last decade, from chemoimmunotherapy (CIT)-based therapies to newer B-cell receptor (BCR) signaling targeting agents, which are sometimes given as continuous schemes. Response to treatment was traditionally defined according to clinical variables designed to assign a response category. Interest in assessing for deeper responses in CLL by the means of measurable residual disease (MRD) testing has been the subject of research during the last several years. Analyses and sub-analyses of clinical trials have shown that achieving undetectable MRD (uMRD) in CLL is an important prognostic factor. In this review, we summarize the available evidence about MRD in CLL, from the various assays available for measurement, the compartment to test, the impact of reaching uMRD according to the treatment regimen, and the results of fixed duration treatment guided by MRD trials. Finally, we summarize how MRD can be incorporated in clinical practice and how it may guide fixed duration treatment in the future should evidence continue to accumulate in that direction.